Top Qs
Timeline
Chat
Perspective
Ethylnaphthylaminopropane
Pharmaceutical compound From Wikipedia, the free encyclopedia
Remove ads
Ethylnaphthylaminopropane (ENAP; developmental code name PAL-1045) is a monoamine releasing agent (MRA) of the amphetamine and naphthylaminopropane families that is related to naphthylaminopropane (NAP; PAL-287) and methamnetamine (MNAP; PAL-1046).[1][2][3] It acts specifically as a serotonin–norepinephrine–dopamine releasing agent (SNDRA).[2][3] However, ENAP is unusual in being a partial releaser of serotonin and dopamine and a full releaser of norepinephrine.[1][2][3]
The EC50 (Emax ) values of ENAP in terms of monoamine release induction are 12 nM (66%) for serotonin, 46 nM (78%) for dopamine, and 137 nM (94%) for norepinephrine in rat brain synaptosomes.[2][3] In contrast to NAP and MNAP, which produce clearly dose-dependent increases in locomotor stimulation and brain monoamine levels in rodents, ENAP has been found to show attenuated monoamine elevations and a "flat" dose–response curve.[4][3] Relatedly, it may have less misuse liability than other drugs like amphetamine, although more research is necessary to assess this possibility.[4][3]
In addition to its MRA activity, ENAP has been found to be an effective pharmacological chaperone for rescuing misfolded mutant monoamine transporters (MATs).[5][6]
Remove ads
See also
References
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads